The FDA Just Voted on BPC-157, TB-500 and Five More Peptides. Here's What Actually Happened.
By PeptideChat Team · July 28, 2026
On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to consider seven peptides that thousands of people already buy online as "research chemicals." The committee voted to recommend six of the seven for the list that would let licensed compounding pharmacies legally prepare them for patients.
If you follow this space, you have probably already seen the headlines — and a good number of them are wrong. This is the most consequential regulatory moment for non-GLP-1 peptides in years, and it is also one of the most widely misread. Here is what the committee actually did, and what it did not do.
The Votes
Each peptide was voted on for a specific, narrow clinical indication — not for general use.
| Peptide | Proposed indication | Vote | Outcome |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | 8-6-1 | Recommended |
| KPV | Inflammatory conditions, wound healing | 8-6-1 | Recommended |
| TB-500 | Wound healing | 8-6-1 | Recommended |
| Semax | Migraine, cerebral ischemia, trigeminal neuralgia | 8-5-1 | Recommended |
| MOTS-c | Osteoporosis, obesity | 7-5-2 | Recommended |
| Epitalon | Insomnia | 7-4-1 | Recommended |
| Emideltide (DSIP) | Insomnia, narcolepsy, opioid withdrawal | 6-7-1 | Not recommended |
Emideltide — better known to most readers as DSIP — was the only one to fail, and it failed by a single vote.
Four Things the Headlines Are Getting Wrong
1. Nothing has legally changed. PCAC recommendations are non-binding. The FDA can accept or reject them, and actually adding a substance to the 503A Bulks List requires formal notice-and-comment rulemaking — a process expected to run into 2027. As of today, every one of these seven remains an unapproved drug. If a vendor tells you the FDA "approved BPC-157" in July 2026, that is not true.
2. "Recommended for compounding" is not "approved," and it is not a finding that the peptide works. Inclusion on the Bulks List is a pharmacy practice designation — it governs what a compounding pharmacy may legally prepare for a patient with a prescription. It is not an efficacy determination and it is not a safety clearance in the sense that an approved drug receives.
3. The FDA's own scientists recommended against all seven. This is the part that has been most consistently dropped from coverage. Agency reviewers published briefing documents opposing every compound on the agenda, citing absent randomized controlled trials, inadequate safety characterization, immunogenicity risk, and poor chemical characterization. The committee overrode its own agency's reviewers on six of seven, by margins as thin as 8-6.
4. The indications are not the ones the community cares about. BPC-157 was voted on for ulcerative colitis — not tendon repair, not gut healing in general, not injury recovery. Epitalon was voted on for insomnia, not longevity. If these eventually reach the Bulks List, a prescription would be written for the voted indication, by a clinician, not for the uses that dominate online discussion.
The TB-500 Finding Deserves Its Own Paragraph
Buried in the coverage is the single most striking fact of the two-day meeting: for TB-500, FDA reviewers could not identify a single human clinical study. Not a small one, not an equivocal one — none.
Committee members also raised a specific mechanistic concern. TB-500 is a fragment of thymosin beta-4, and one member flagged the overlap between thymosin beta-4's normal biological function and its documented ability to promote tumor progression and metastasis. The same properties that make a peptide interesting for tissue repair — angiogenesis, cell migration, proliferation — are properties you do not necessarily want amplified if there is an undetected malignancy present.
TB-500 was still recommended, 8-6-1. Both facts are true at once, and anyone considering this compound should sit with that.
What This Actually Means
The honest read is that this was a narrow, contested vote that starts a long process, not a finish line. Three scenarios are all still live: the FDA follows the committee and begins rulemaking; the FDA declines, as it has done with PCAC recommendations before; or some compounds advance and others stall.
What would change if rulemaking does complete? Quite a lot, actually. These compounds would move from a legal gray market — where "research use only" labeling is a fig leaf and nobody is accountable for what is in the vial — into licensed pharmacies operating under state boards, with real quality standards and a prescriber in the loop. That is a genuine improvement in safety, whatever you think of the evidence base.
But that is a 2027-and-beyond question. Today, the practical situation for every peptide on that list is exactly what it was in June.
The Takeaway
Six of seven peptides cleared a non-binding advisory vote, against FDA staff advice, for narrow clinical indications, with rulemaking still ahead. That is real news and it is worth watching closely. It is not approval, it is not a safety finding, and it does not make anything legal to sell for human use today.
The most useful thing you can do with this news is treat it as a prompt to read the actual evidence base for whichever compound interests you — including, in TB-500's case, the fact that the FDA could not find any human trials at all.
This article is for research and educational purposes only. It is not medical advice, and it does not endorse the purchase or use of any compound. The peptides discussed are not FDA-approved for human use.